Victrelis

Figure 4. Cost per cure for cirrhotic genotype 1 patients (by treatment regime) Hepatitis C Virus (HCV) is a global health… Expand

The US Food and Drug Administration (FDA) approvals of Gilead’s Sovaldi (sofosbuvir) on December 6 and, to a lesser extent, of… Expand

The Hepatitis C virus infects an estimated 170 million people worldwide, and is the major cause of hepatitis, cirrhosis and liver… Expand

 

Resumen Recientemente, la Agencia Europea del Medicamento ha aprobado el uso de telaprevir (Incivo ® , Janssen) y boceprevir… Expand

 

Merck & Co. and Roche, two rivals in the hepatitis C virus (HCV) market, have joined forces in a broad, non-exclusive… Expand

for people on Victrelis-based triple therapy. But the newly approved drugs also have major shortcomings, adding an extra safety… Expand

Following approval of hepatitis C virus protease inhibitors Incivek and Victrelis, companies are partnering to devise all-oral… Expand

Chronic viral hepatitis B and C are a significant cause of chronic liver disease worldwide and still represent a pathology… Expand